No material catalyst — MEAI remains preclinical for intranasal delivery. Monitor for clinical trial initiation or partnering deals. Given $2M market cap, any positive regulatory or clinical event could drive outsized moves, but this filing alone is not actionable.
Price Chart
Executive Summary
Clearmind Medicine announced positive ex vivo mucoadhesion results for its intranasal formulation of MEAI, demonstrating improved nasal retention compared to a standard solution. This is a preclinical formulation milestone, not a clinical efficacy result, and does not alter the company's near-term cash runway or regulatory outlook for a $2M market-cap clinical-stage biotech.
Key Facts
- Ex vivo mucoadhesion study on rabbit nasal mucosa showed intranasal MEAI formulation maintained greater proportion of adhered dose over 30 minutes vs standard solution
- Formulation uses mucoadhesive polymer system to improve nasal residence time
- Study is part of intranasal MEAI development program for Alcohol Use Disorder (AUD)
- Clearmind reports 19 patent families and 32 granted patents
- Filing is a routine 6-K furnished with registration statement incorporation by reference
Financial Impact
No financial figures disclosed; preclinical formulation study with no direct revenue or cost impact
Risk Factors
- Ex vivo mucoadhesion results may not translate to in vivo absorption or clinical efficacy
- MEAI intranasal program is still preclinical; regulatory and clinical development risks remain high
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 10 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (CMND) — Batch item 1 | 0001213900-26-078630 |
| Document: ea0298239-6k_clearmind.htm | 0001213900-26-078630 |
| Document: 0001213900-26-078630-index-headers.html | 0001213900-26-078630 |
| Document: 0001213900-26-078630-index.html | 0001213900-26-078630 |
| Document: 0001213900-26-078630.txt | 0001213900-26-078630 |
| 6-K Filing (CMND) — Batch item 6 | 0001213900-26-078630 |
| Document: ea0298239-6k_clearmind.htm | 0001213900-26-078630 |
| Document: 0001213900-26-078630-index-headers.html | 0001213900-26-078630 |
| Document: 0001213900-26-078630-index.html | 0001213900-26-078630 |
| Document: 0001213900-26-078630.txt | 0001213900-26-078630 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $5.92 | awaiting T+60 | — | $5.95 (+0.47%) |
Oct 27, 2026 today | Press Release | $6.50 | awaiting T+60 | — | $5.95 (−8.50%) |
Oct 16, 2026 10d ago | 6-K | $6.00 | awaiting T+60 | — | $5.95 (+0.87%) |
Oct 13, 2026 14d ago | 6-K | $6.23 | awaiting T+60 | — | $5.95 (−4.53%) |
Oct 8, 2026 19d ago | 6-K | $6.60 | awaiting T+60 | — | $5.95 (−9.88%) |
Oct 7, 2026 20d ago | 6-K | $6.60 | awaiting T+60 | — | $5.95 (−9.88%) |
Sep 23, 2026 4w ago | 6-K | $0.8500 | awaiting T+60 | — | $5.95 (+599.72%) |
Sep 23, 2026 4w ago | Press Release | $0.8500 | awaiting T+60 | — | $5.95 (+599.72%) |
Sep 17, 2026 5w ago | Press Release | $6.86 | awaiting T+60 | — | $5.95 (−13.35%) |
Sep 14, 2026 6w ago | 6-K | $0.9440 | awaiting T+60 | — | $5.95 (+530.04%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers